Emre Atilgan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emre Atilgan has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Hasan Murat Ertuğrul
Department of Economics, Faculty of Economics and Administrative Sciences, Anadolu University, Eskisehir, Turkey
2 shared publications Ahmet Yasir Barak
Affiliation Department of Accounting and Finance, Isparta Applied Sciences University, Isparta, Türkiye
1 shared publicationAlev Bakir
Department of Biostatistics and Medical Informatics, Faculty of Medicine, T.C. Halic University, Istanbul, Turkey
1 shared publication- Alper Ozun
Department of Economics, University of Cambridge, The Austin Robinson Building, Sidgwick Ave, Cambridge CB3 9DD, UK
1 shared publication - Arzu Ay
Department of Biophysics, Faculty of Medicine, Trakya University, Edirne 22030, Turkey
1 shared publication Aysu Zekioğlu
Department of Health Management, Faculty of Health Sciences, Trakya University, Edirne, Turkey
1 shared publication
Latest Publications
- 27 November 2025
- Published by Elsevier in Health Policy
- Vol. 164, 105504
Understanding the intention–action gap in physician migration during crises: Interrupted time-series evidence from Turkey
- 27 November 2025
- Published by Elsevier in Health Policy
- Vol. 164, 105504
Understanding the intention–action gap in physician migration during crises: Interrupted time-series evidence from Turkey
- Open Access
- 27 October 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0334970
The impact of patent activity on idiosyncratic volatility in U.S. pharmaceutical companies
This study examines the impact of patent activity on the idiosyncratic volatility (IVOL) of U.S. pharmaceutical companies, addressing a critical gap in the literature on the relationship between innovation and firm-specific risk. Using panel data from Thomson Reuters/Refinitiv covering 2,910 firms over 2005−2024, we employ the Fama-French 5-factor model to isolate firm-specific volatility and analyze how patent events and pharmaceutical development activities affect stock price risk. Our findings reveal a complex relationship between innovation and volatility that varies by development stage. While patent activity overall reduces idiosyncratic volatility, early and mid-stage development projects (Phase I and II) initially increase firm-specific risk, reflecting inherent uncertainties in drug development. Conversely, newly launched products significantly reduce volatility, indicating that risk mitigation occurs primarily at commercialization. These relationships remain robust during crisis periods, including the 2008−09 financial crisis and COVID-19 pandemic. The results provide valuable insights for investors seeking to assess pharmaceutical investment risks, managers optimizing innovation portfolios, and policymakers designing intellectual property frameworks. The study’s focus on the U.S. market and reliance on patent counts rather than quality measures suggest important avenues for future research across different regulatory environments and innovation metrics.
- 27 October 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0334970
Open AccessThe impact of patent activity on idiosyncratic volatility in U.S. pharmaceutical companies
This study examines the impact of patent activity on the idiosyncratic volatility (IVOL) of U.S. pharmaceutical companies, addressing a critical gap in the literature on the relationship between innovation and firm-specific risk. Using panel data from Thomson Reuters/Refinitiv covering 2,910 firms over 2005−2024, we employ the Fama-French 5-factor model to isolate firm-specific volatility and analyze how patent events and pharmaceutical development activities affect stock price risk. Our findings reveal a complex relationship between innovation and volatility that varies by development stage. While patent activity overall reduces idiosyncratic volatility, early and mid-stage development projects (Phase I and II) initially increase firm-specific risk, reflecting inherent uncertainties in drug development. Conversely, newly launched products significantly reduce volatility, indicating that risk mitigation occurs primarily at commercialization. These relationships remain robust during crisis periods, including the 2008−09 financial crisis and COVID-19 pandemic. The results provide valuable insights for investors seeking to assess pharmaceutical investment risks, managers optimizing innovation portfolios, and policymakers designing intellectual property frameworks. The study’s focus on the U.S. market and reliance on patent counts rather than quality measures suggest important avenues for future research across different regulatory environments and innovation metrics.
- 1 January 2025
- Published by Efe Akademi Yayınları
Sağlık Ekonomisi Perspektifinde Dijital Dönüşüm
Bu kitap, dijital sağlık teknolojilerinin ekonomik yönlerinin kapsamlı ve sistematik bir şekilde incelenmesi ihtiyacına yanıt vermektedir. Literatürde dijital sağlık uygulamalarının teknik boyutları sıklıkla ele alınmakla birlikte, ekonomik etkiler, maliyet-etkinlik dinamikleri ve uzun vadeli sürdürülebilirlik açısından bütüncül değerlendirme yapan kaynaklar sınırlıdır. Eser, dijital sağlık ekonomisinin teorik temellerinden başlayarak, uygulama örneklerine, etik ve düzenleyici sorunlardan geleceğe yönelik projeksiyonlara kadar geniş bir yelpazede analizler sunmaktadır. Teletıp ve sanal sağlık hizmetlerinin ekonomik değerlendirmeleri, kişiselleştirilmiş tıp uygulamalarının maliyet-etkinlik potansiyeli, dijital eşitsizliklerin ekonomik maliyetleri ve algoritmik önyargıların finansal etkileri gibi konular, teorik çerçeveler ve güncel ampirik bulgularla ele alınmaktadır. Kitapta, dijital bölünmenin yalnızca teknik bir erişim sorunu olmadığı, aynı zamanda ciddi ekonomik sonuçları olan sistemik bir mesele olduğu vurgulanmaktadır. Yapay zekâ destekli sağlık uygulamalarının, sağlık adaletini artırma potansiyeli ile eşitsizlikleri derinleştirme riskleri, çok boyutlu ekonomik analizlerle ortaya konulmaktadır. Eser, sağlık ekonomistleri ve politika araştırmacıları için kavramsal çerçeveler sağlamakta, sağlık yöneticileri ve teknoloji geliştiriciler için ise uygulanabilir değerlendirme araçları sunmaktadır. Kitapta yer verilen politika önerileri, ulusal stratejilerin oluşturulmasından uluslararası iş birliği ve düzenleyici koordinasyona kadar çeşitli alanlarda çözüm perspektifleri içermektedir.
- 1 January 2025
- Published by Efe Akademi Yayınları
Sağlık Ekonomisi Perspektifinde Dijital Dönüşüm
Bu kitap, dijital sağlık teknolojilerinin ekonomik yönlerinin kapsamlı ve sistematik bir şekilde incelenmesi ihtiyacına yanıt vermektedir. Literatürde dijital sağlık uygulamalarının teknik boyutları sıklıkla ele alınmakla birlikte, ekonomik etkiler, maliyet-etkinlik dinamikleri ve uzun vadeli sürdürülebilirlik açısından bütüncül değerlendirme yapan kaynaklar sınırlıdır. Eser, dijital sağlık ekonomisinin teorik temellerinden başlayarak, uygulama örneklerine, etik ve düzenleyici sorunlardan geleceğe yönelik projeksiyonlara kadar geniş bir yelpazede analizler sunmaktadır. Teletıp ve sanal sağlık hizmetlerinin ekonomik değerlendirmeleri, kişiselleştirilmiş tıp uygulamalarının maliyet-etkinlik potansiyeli, dijital eşitsizliklerin ekonomik maliyetleri ve algoritmik önyargıların finansal etkileri gibi konular, teorik çerçeveler ve güncel ampirik bulgularla ele alınmaktadır. Kitapta, dijital bölünmenin yalnızca teknik bir erişim sorunu olmadığı, aynı zamanda ciddi ekonomik sonuçları olan sistemik bir mesele olduğu vurgulanmaktadır. Yapay zekâ destekli sağlık uygulamalarının, sağlık adaletini artırma potansiyeli ile eşitsizlikleri derinleştirme riskleri, çok boyutlu ekonomik analizlerle ortaya konulmaktadır. Eser, sağlık ekonomistleri ve politika araştırmacıları için kavramsal çerçeveler sağlamakta, sağlık yöneticileri ve teknoloji geliştiriciler için ise uygulanabilir değerlendirme araçları sunmaktadır. Kitapta yer verilen politika önerileri, ulusal stratejilerin oluşturulmasından uluslararası iş birliği ve düzenleyici koordinasyona kadar çeşitli alanlarda çözüm perspektifleri içermektedir.
- Open Access
- 24 July 2024
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 12, 1437304
Health-led growth hypothesis and health financing systems: an econometric synthesis for OECD countries
Introduction: This study investigates the Health-Led Growth Hypothesis (HLGH) within OECD countries, examining how health expenditures influence economic growth and the role of different health financing systems in this relationship.Methods: Utilizing a comprehensive analysis spanning 2000 to 2019 across 38 OECD countries, advanced econometric methodologies were employed. Both second-generation panel data estimators (Dynamic CCEMG, CS-ARDL, AMG) and first-generation models (Panel ARDL with PMG, FMOLS, DOLS) were utilized to test the hypothesis.Results: The findings confirm the positive impact of health expenditures on economic growth, supporting the HLGH. Significant disparities were observed in the ability of health expenditures to stimulate economic growth across different health financing systems, including the Bismarck, Beveridge, Private Health Insurance, and System in Transition models.Discussion: This study enriches the ongoing academic dialog by providing an exhaustive analysis of the relationship between health expenditures and economic growth. It offers valuable insights for policymakers on how to optimize health investments to enhance economic development, considering the varying effects of different health financing frameworks.
- 24 July 2024
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 12, 1437304
Open AccessHealth-led growth hypothesis and health financing systems: an econometric synthesis for OECD countries
Introduction: This study investigates the Health-Led Growth Hypothesis (HLGH) within OECD countries, examining how health expenditures influence economic growth and the role of different health financing systems in this relationship.Methods: Utilizing a comprehensive analysis spanning 2000 to 2019 across 38 OECD countries, advanced econometric methodologies were employed. Both second-generation panel data estimators (Dynamic CCEMG, CS-ARDL, AMG) and first-generation models (Panel ARDL with PMG, FMOLS, DOLS) were utilized to test the hypothesis.Results: The findings confirm the positive impact of health expenditures on economic growth, supporting the HLGH. Significant disparities were observed in the ability of health expenditures to stimulate economic growth across different health financing systems, including the Bismarck, Beveridge, Private Health Insurance, and System in Transition models.Discussion: This study enriches the ongoing academic dialog by providing an exhaustive analysis of the relationship between health expenditures and economic growth. It offers valuable insights for policymakers on how to optimize health investments to enhance economic development, considering the varying effects of different health financing frameworks.
- 3 June 2024
- Published by Elsevier in Resources Policy
- Vol. 94
Fintech: A Conduit for sustainability and renewable energy? Evidence from R2 connectedness analysis
- 3 June 2024
- Published by Elsevier in Resources Policy
- Vol. 94
Fintech: A Conduit for sustainability and renewable energy? Evidence from R2 connectedness analysis
- Open Access
- 8 September 2017
- Published by Taylor & Francis in Biotechnology & Biotechnological Equipment
- Vol. 31 (6) , 1184-1191
Calcitonin related polypeptide alpha gene polymorphisms according to plasma total homocysteine levels in ischemic stroke patients of Trakya Region
The aim of this study was to determine the genotype distributions of calcitonin related polypeptide alpha (CALCA) gene polymorphisms according to the plasma total homocysteine levels in ischemic stroke patients and patient subtypes selected from Trakya Region. The study included 82 patients and 92 healthy controls. Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) were used to determine the genotype distributions of CALCA gene polymorphisms. The plasma total homocysteine levels were measured by Immulite 2000XPi homocysteine kits. Significant differences were not found between the group of patients and the control group in terms of CALCA gene polymorphisms genotype distributions (p > 0.05). Significant differences were not found between ischemic stroke patients and healthy controls, in the patient subtypes with ischemic stroke in respect to the CALCA gene polymorphisms genotype distributions according to the plasma total homocysteine levels (p > 0.05). This suggests that the CALCA gene polymorphisms genotype distributions studied according to the plasma total homocysteine levels could not likely be considered a genetic risk factor for ischemic stroke development.
- 8 September 2017
- Published by Taylor & Francis in Biotechnology & Biotechnological Equipment
- Vol. 31 (6) , 1184-1191
Open AccessCalcitonin related polypeptide alpha gene polymorphisms according to plasma total homocysteine levels in ischemic stroke patients of Trakya Region
The aim of this study was to determine the genotype distributions of calcitonin related polypeptide alpha (CALCA) gene polymorphisms according to the plasma total homocysteine levels in ischemic stroke patients and patient subtypes selected from Trakya Region. The study included 82 patients and 92 healthy controls. Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) were used to determine the genotype distributions of CALCA gene polymorphisms. The plasma total homocysteine levels were measured by Immulite 2000XPi homocysteine kits. Significant differences were not found between the group of patients and the control group in terms of CALCA gene polymorphisms genotype distributions (p > 0.05). Significant differences were not found between ischemic stroke patients and healthy controls, in the patient subtypes with ischemic stroke in respect to the CALCA gene polymorphisms genotype distributions according to the plasma total homocysteine levels (p > 0.05). This suggests that the CALCA gene polymorphisms genotype distributions studied according to the plasma total homocysteine levels could not likely be considered a genetic risk factor for ischemic stroke development.
- 3 June 2016
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 18 (5) , 567-574
The dynamic relationship between health expenditure and economic growth: is the health-led growth hypothesis valid for Turkey?
The well-known health-led growth hypothesis claims a positive correlation between health expenditure and economic growth. The aim of this paper is to empirically investigate the health-led growth hypothesis for the Turkish economy. The bound test approach, autoregressive-distributed lag approach (ARDL) and Kalman filter modeling are employed for the 1975–2013 period to examine the co-integration relationship between economic growth and health expenditure. The ARDL model is employed in order to investigate the long-term and short-term static relationship between health expenditure and economic growth. The results show that a 1 % increase in per-capita health expenditure will lead to a 0.434 % increase in per-capita gross domestic product. These findings are also supported by the Kalman filter model’s results. Our findings show that the health-led growth hypothesis is supported for Turkey.
- 3 June 2016
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 18 (5) , 567-574
The dynamic relationship between health expenditure and economic growth: is the health-led growth hypothesis valid for Turkey?
The well-known health-led growth hypothesis claims a positive correlation between health expenditure and economic growth. The aim of this paper is to empirically investigate the health-led growth hypothesis for the Turkish economy. The bound test approach, autoregressive-distributed lag approach (ARDL) and Kalman filter modeling are employed for the 1975–2013 period to examine the co-integration relationship between economic growth and health expenditure. The ARDL model is employed in order to investigate the long-term and short-term static relationship between health expenditure and economic growth. The results show that a 1 % increase in per-capita health expenditure will lead to a 0.434 % increase in per-capita gross domestic product. These findings are also supported by the Kalman filter model’s results. Our findings show that the health-led growth hypothesis is supported for Turkey.
- Open Access
- 4 January 2016
- Published by Uluslararasi Insan Bilimleri Dergisi in Journal of Human Sciences
- Vol. 13 (1) , 695-712
An assessment for Public Hospitals Associations' performance measurement approachKamu Hastaneleri Birlikleri performans ölçüm yöntemi üzerine bir değerlendirme
Health Transformation Program (HTP) was launched in 2003 with the primary aim of achieving effectiveness, efficiency, and equity in organization, delivery, and financing of health care services in Turkey. In the final leg of the program, the Public Hospital Associations (PHA), which are basically the regional hospital unions, were announced in 2011 with the legislative decree no.663 and have been in operation since fall 2012. Establishment of the PHAs introduced a new management approach for Turkish public hospitals. This model based on a new managerial performance assessment approach, which was developed to evaluate the hospitals’ performances in many dimension, including medical, administrative, financial, quality, patient safety, employee-satisfaction and education aspects. In this regard, the Turkish Public Hospitals Institution (PHI), which is the highest institution that rules all the public hospitals, has begun to use modified version of Balanced Score Card (BSC) approach to assess the managerial performance of the PHAs. In this approach, production efficiency scores of hospitals, which are estimated with Stochastic Frontier Analysis (SFA), became a key or a target indicator for hospital performance assessment. In this paper, the performance measurement approach of the PHAs is assessed with respect to the theoretical methods used in this approach, i.e. BSC and SFA efficiency methods. ÖzetSağlıkta Dönüşüm Programı (SDP), Türkiye’de sağlık hizmetlerinin organizasyon, sunum ve finansmanında etkililik, etkinlik ve hakkaniyet sağlamak amacıyla 2003 yılında uygulamaya konulmuştur. Programın son ayağında, basit anlamda hastanelerin yönetimsel olarak birleşmesi ifade eden Kamu Hastaneleri Birlikleri (KHB), 2011 yılında 663 nolu KHK ile kurulmuş ve 2012 yılında faaliyete başlamıştır. KHB’lerin kurulmasıyla birlikte Türkiye kamu hastaneleri için yeni bir yönetim yaklaşımı oluşturulmuştur. Bu yaklaşım, hastanelerin performansını, tıbbi, idari, mali, kalite, hasta ve Çalışan güvenliği-memnuniyeti ile eğitim boyutlarında değerlendirilmesini amacıyla geliştirilmiş olan yönetimsel performans modeli üzerine kurulmuştur. Uygulamaya konulan yeni sistemde, kamu hastanelerinin yönetici kuruluşu olan Türkiye Kamu Hastaneleri Kurumu (TKHK), KHB’lerin yönetimsel performansının değerlendirilmesi için, Dengeli Skor Kartı (DSK) yaklaşımının uyarlanmış bir şeklini kullanmaya başlamıştır. Bu yaklaşımda, Stokastik Sınır Analizi yöntemiyle hesaplanan hastane üretim etkinlik skorları, hastane performansının belirlenmesinde anahtar ya da hedef gösterge olmuştur. Bu çalışmada Kamu Hastaneleri Birlikleri performans değerlendirme modelinin, modelin kullandığı DSK ve SSA yöntemleri çerçevesinde bir değerlendirmesi sunulmaktadır.
- 4 January 2016
- Published by Uluslararasi Insan Bilimleri Dergisi in Journal of Human Sciences
- Vol. 13 (1) , 695-712
Open AccessAn assessment for Public Hospitals Associations' performance measurement approachKamu Hastaneleri Birlikleri performans ölçüm yöntemi üzerine bir değerlendirme
Health Transformation Program (HTP) was launched in 2003 with the primary aim of achieving effectiveness, efficiency, and equity in organization, delivery, and financing of health care services in Turkey. In the final leg of the program, the Public Hospital Associations (PHA), which are basically the regional hospital unions, were announced in 2011 with the legislative decree no.663 and have been in operation since fall 2012. Establishment of the PHAs introduced a new management approach for Turkish public hospitals. This model based on a new managerial performance assessment approach, which was developed to evaluate the hospitals’ performances in many dimension, including medical, administrative, financial, quality, patient safety, employee-satisfaction and education aspects. In this regard, the Turkish Public Hospitals Institution (PHI), which is the highest institution that rules all the public hospitals, has begun to use modified version of Balanced Score Card (BSC) approach to assess the managerial performance of the PHAs. In this approach, production efficiency scores of hospitals, which are estimated with Stochastic Frontier Analysis (SFA), became a key or a target indicator for hospital performance assessment. In this paper, the performance measurement approach of the PHAs is assessed with respect to the theoretical methods used in this approach, i.e. BSC and SFA efficiency methods. ÖzetSağlıkta Dönüşüm Programı (SDP), Türkiye’de sağlık hizmetlerinin organizasyon, sunum ve finansmanında etkililik, etkinlik ve hakkaniyet sağlamak amacıyla 2003 yılında uygulamaya konulmuştur. Programın son ayağında, basit anlamda hastanelerin yönetimsel olarak birleşmesi ifade eden Kamu Hastaneleri Birlikleri (KHB), 2011 yılında 663 nolu KHK ile kurulmuş ve 2012 yılında faaliyete başlamıştır. KHB’lerin kurulmasıyla birlikte Türkiye kamu hastaneleri için yeni bir yönetim yaklaşımı oluşturulmuştur. Bu yaklaşım, hastanelerin performansını, tıbbi, idari, mali, kalite, hasta ve Çalışan güvenliği-memnuniyeti ile eğitim boyutlarında değerlendirilmesini amacıyla geliştirilmiş olan yönetimsel performans modeli üzerine kurulmuştur. Uygulamaya konulan yeni sistemde, kamu hastanelerinin yönetici kuruluşu olan Türkiye Kamu Hastaneleri Kurumu (TKHK), KHB’lerin yönetimsel performansının değerlendirilmesi için, Dengeli Skor Kartı (DSK) yaklaşımının uyarlanmış bir şeklini kullanmaya başlamıştır. Bu yaklaşımda, Stokastik Sınır Analizi yöntemiyle hesaplanan hastane üretim etkinlik skorları, hastane performansının belirlenmesinde anahtar ya da hedef gösterge olmuştur. Bu çalışmada Kamu Hastaneleri Birlikleri performans değerlendirme modelinin, modelin kullandığı DSK ve SSA yöntemleri çerçevesinde bir değerlendirmesi sunulmaktadır.
- Open Access
- 1 October 2015
- Published by Iktisat Isletme ve Finans Dergisi in İktisat İşletme ve Finans
- Vol. 30 (355)
The Cost Efficiency of Turkish Hospitals: A Stochastic Frontier Analysis
- 1 October 2015
- Published by Iktisat Isletme ve Finans Dergisi in İktisat İşletme ve Finans
- Vol. 30 (355)
Open AccessThe Cost Efficiency of Turkish Hospitals: A Stochastic Frontier Analysis
- 23 August 2015
- Published by Springer Nature in International Journal of Public Health
- Vol. 60 (7) , 815-825
Equity in maternal health care service utilization: a systematic review for developing countries
The objective was to explore progress of equity in the utilization of maternal health care services in developing countries since maternal care is a crucial factor in reducing maternal mortality, which is targeted by the Millennium Development Goal 5. A systematic review of quantitative studies was done. PubMed Central, Web of Science, and Science Direct databases were searched for peer-reviewed and English-language articles published between 2005 and 2015. Thirty-six articles were included in the review. The results reveal the lack of equity in the utilization of maternal health care in developing countries. Thirty-three out of 36 studies found evidence supporting severe inequities while three studies found evidence of equity or at least improvement in terms of equity. Most of the literature devoted to utilization of maternal health care generally provides information on the level of maternal care used and ignore the equity problem. Research in this area should focus not only on the level of maternal care used but also on the most disadvantaged segments of the population in terms of utilization of maternal care in order to reach the set targets.
- 23 August 2015
- Published by Springer Nature in International Journal of Public Health
- Vol. 60 (7) , 815-825
Equity in maternal health care service utilization: a systematic review for developing countries
The objective was to explore progress of equity in the utilization of maternal health care services in developing countries since maternal care is a crucial factor in reducing maternal mortality, which is targeted by the Millennium Development Goal 5. A systematic review of quantitative studies was done. PubMed Central, Web of Science, and Science Direct databases were searched for peer-reviewed and English-language articles published between 2005 and 2015. Thirty-six articles were included in the review. The results reveal the lack of equity in the utilization of maternal health care in developing countries. Thirty-three out of 36 studies found evidence supporting severe inequities while three studies found evidence of equity or at least improvement in terms of equity. Most of the literature devoted to utilization of maternal health care generally provides information on the level of maternal care used and ignore the equity problem. Research in this area should focus not only on the level of maternal care used but also on the most disadvantaged segments of the population in terms of utilization of maternal care in order to reach the set targets.